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STUDY PROTOCOL Open Access
The Patient Remote Intervention and Symptom
Management System (PRISMS) – a Telehealth-
mediated intervention enabling real-time
monitoring of chemotherapy side-effects in
patients with haematological malignancies:
study protocol for a randomised controlled trial
Sibilah Breen1,2,3*, David Ritchie3,5,6,7, Penelope Schofield2,3,8, Ya-seng Hsueh9, Karla Gough1, Nick Santamaria2,3,10,
Rose Kamateros1, Roma Maguire11, Nora Kearney11 and Sanchia Aranda1,2,4
Abstract
Background: Outpatient chemotherapy is a core treatment for haematological malignancies; however, its toxicities
frequently lead to distressing/potentially life-threatening side-effects (neutropenia/infection, nausea/vomiting, mucositis,
constipation/diarrhoea, fatigue). Early detection/management of side-effects is vital to improve patient outcomes,
decrease morbidity and limit lengthy/costly hospital admissions. The ability to capture patient-reported health data in
real-time, is regarded as the ‘gold-standard’ to allow rapid clinical decision-making/intervention. This paper presents the
protocol for a Phase 3 multi-site randomised controlled trial evaluating a novel nurse-led Telehealth intervention for
remote monitoring/management of chemotherapy side-effects in Australian haematological cancer patients.
Methods/Design: Two hundred and twenty-two patients will be recruited from two hospitals. Eligibility criteria
include: diagnosis of chronic lymphocytic leukaemia/Hodgkin’s/non-Hodgkin’s lymphoma; aged≥ 18 years; receiving
≥ 2 cycles chemotherapy. Patients will be randomised 1:1 to either the control or intervention arm with stratification by
diagnosis, chemotherapy toxicity (high versus low), receipt of previous chemotherapy and hospital. Patients allocated
to the control arm will receive ‘Usual Care’ whilst those allocated to the intervention will receive the intervention in
addition to ‘Usual Care’. Intervention patients will be provided with a computer tablet and software prompting
twice-daily completion of physical/emotional scales for up to four chemotherapy cycles. Should patient data exceed
pre-determined limits an Email alert is delivered to the treatment team, prompting nurses to view patient data, and
contact the patient to provide clinical intervention. In addition, six scheduled nursing interventions will be completed
to educate/support patients in use of the software. Patient outcomes will be measured cyclically (midpoint and end of
cycles) via pen-and-paper self-report alongside review of the patient medical record. The primary outcome is burden
due to nausea, mucositis, constipation and fatigue. Secondary outcomes include: burden due to vomiting and
diarrhoea; psychological distress; ability to self-manage health; level of cancer information/support needs and;
utilisation of health services. Analyses will be intention-to-treat. A cost-effectiveness analysis is planned.
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Discussion: This trial is the first in the world to test a remote monitoring/management intervention for adult
haematological cancer patients receiving chemotherapy. Future use of such interventions have the potential to
improve patient outcomes/safety and decrease health care costs by enabling early detection/clinical intervention.
Trial registration: ACTRN12614000516684.
Date registered: 12 March 2014 (registered retrospectively).
Keywords: Telehealth, ASyMS, Nursing, Chemotherapy, Side-effects, Cancer, Lymphoma, Leukaemia, Protocol
Background
Haematological malignancies (including lymphomas and
leukaemias) account for around 10 % of new cancer
diagnoses in Australia [1] and are the sixth most preva-
lent form of cancer overall, with lymphomas being the
most commonly diagnosed cancer in the 15–24 year
age-group [1]. Chemotherapy is a core treatment for
haematological malignancies; however, its toxicities often
lead to potentially life-threatening or distressing side-
effects (eg febrile neutropenia, infections, mucositis,
nausea, vomiting, fatigue) [2–6]. Toxicities such as mu-
cositis are more commonly experienced in haemato-
logical maligancies than solid tumours [6] and are
associated with poorer treatment adherence, impaired
quality of life, increased infections, mortality, hospitalisa-
tions and ultimately with a higher cost/economic burden
to the health care system [7–12].
Need for real-time assessment of side-effects
The early detection of side-effects such as severe mucosi-
tis and febrile neutropenia is vital, as they are potentially
life-threatening and often lead to costly hospital admis-
sions and higher patient morbidity, especially in haemato-
logical cancers [2, 7, 8, 12]. Management of non-life-
threatening side-effects, such as fatigue, are also important
as they impact on quality of life, daily living activities and
may result in mood disturbance [11]. High symptom bur-
den is also a known risk factor for adverse psychological
adjustment in people with cancer [13, 14].
People with haematological cancers receive chemo-
therapy in either day treatment units or in-patient
settings, followed by discharge into the community.
Patients are required to monitor their side-effects at
home but may be reluctant to inform their treatment
team when problems arise [15]. Structured symptom
assessment tools and the implementation of timely
management strategies improve patient physical and
emotional outcomes [16–18], but traditionally rely on
retrospective patient recall (from their previous ap-
pointment or treatment), are prone to recall bias [19]
and impede timely clinical responses. The ability to
capture patient-reported symptom data in real-time is,
therefore, the ‘gold standard’ to allow rapid clinical
decision-making and interventions to improve patient
outcomes.
Need for patient self-management of side-effects and the
role of the specialist nurse
Patients discharged into the community setting fol-
lowing each chemotherapy treatment cycle are also
required to monitor their health and engage in self-
care activities to prevent, or reduce, the severity of
numerous, and possibly complex side-effects. In
addition, patients often report the need ‘to be in-
formed about the things you can do to help yourself
get well’ [20]. Developing patients’ self-care skills is
critically important to ensure safe and high quality
care at home. Previous studies examining the nurse’s
role in promoting patient self-care demonstrate the
potential of nurses to reduce psychological distress
[13], reduce patient concerns about treatment [13],
decrease barriers to self-care [21] and improve symptoms
[13] using short duration nurse-led interventions. Various
strategies have also been used to boost these interventions
including, evidence-based messages via DVD [13], or
telephone follow-up, in addition to face-to-face ses-
sions [13, 21]. Despite positive results, these interven-
tions were hampered by the inability to respond to
patient concerns in real-time. Systematic reviews in
cancer [22], and chronic disease [23], conclude that
research, in particular intervention studies, are a priority
to guide practice to improve patient self-management.
Telehealth systems can improve patient outcomes
The International Organisation for Standardisation de-
fines Telehealth as the ‘Use of telecommunication tech-
niques for the purpose of providing telemedicine,
medical education and health education over a distance’
[24]. More specifically this relates to the real-time re-
mote exchange of physiological or symptom data be-
tween patients in the community and clinicians within a
treatment facility and includes: the Internet; phone lines
(land or mobile); or video links. To date, technology has
enabled successful assessment of symptoms in patients
with chronic disease resulting in improved patient out-
comes and decreased hospital stays/health system costs
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[25–32]. However, few studies report Telehealth systems
for cancer patients and most only focus on acceptability,
feasibility or useability data [33]. Only five papers to date
attempt to quantify benefits in patients with cancer
(eg during chemotherapy treatment; post-surgery)
which include: decreases in fatigue, pain, depression,
post-operative symptom threshold events; interference
with activities of daily living and; preventable use of
health care services (eg clinic visits, bed days of care)
[34–38]. Despite the promising early findings, all
Telehealth research in cancer to date has serious
limitations including sub-optimal study design (in-
sufficient power, no record of patient adherence to
self-care/intervention adherence) or health economic
analyses [33]. In addition, no cancer Telehealth sys-
tems have incorporated explicit coaching of patients
in the self-care advice delivered; or have been de-
veloped for use with high-risk clinical groups or
within an Australian context [33].
Development of a remote monitoring system for
haematological cancer patients
Given the early success of the Advanced Symptom
Management System (ASyMS) developed in the UK
by Kearney and colleagues, a remote-monitoring sys-
tem used in a range of patient settings [36, 39–42] a
collaboration to develop a remote monitoring system
specifically for Australian patients with haematological
cancers (i.e. those at increased risk of chemotherapy
toxicities) was undertaken. ASyMS uses a touch
screen mobile phone application to collect daily data
about patient chemotherapy side-effects. Side-effects
which exceed pre-determined limits (as assessed by
underlying software algorithms) create alerts in real-time
to the hospital treatment team who would log into the se-
cure system website, review patient data and contact the
patient for further assessment/clinical intervention. The
application also provided tailored self-care for patients
reporting side-effects alongside plotting side-effect data
over time.
Content for the Australian system to be utilised by
haematological cancer patients (i.e. side-effects moni-
tored, evidence-based self-care advice and alerting
algorithms) was developed following a review of the
literature and extensive consultation with haematol-
ogy nurses, clinicians and patients. The system was
piloted and found to be highly acceptable to both pa-
tients and clinicians with feedback around content
and functionality used to improve the system [43].
However, it was noted that some patients required
additional/ongoing support to utilise the full func-
tionality of the remote monitoring system; to under-
stand that system alerts were expected from
patients receiving treatment and; that patients
should not feel uncomfortable or guilty about trig-
gering these alerts [43].
Value adding to remote side-effect monitoring
It is important that Telehealth systems evolve to combine
ongoing human contact (eg nurse coaching/support) with
technology delivered care, rather than relying on the
technology alone. This means that a remote monitor-
ing system is only part of a structured patient inter-
vention. A vital addition to ASyMS in the Australian
system is an evidence-based nursing intervention, in-
cluding patient education and coaching in self-care.
Coaching patients in self-care is associated with im-
proved patient outcomes/decreased psychological dis-
tress [22, 23] and previous studies have identified that
nurse-led interventions focusing on patient education
and self-care coaching can improve patient outcomes
[13, 21]. However, these study results were limited by
not being able to respond to patient side-effects in
real-time. Telehealth, therefore, have the potential to
influence supportive care outcomes by assisting nurses to
respond to a patient’s actual symptoms with evidenced-
based self-care, rather than preparing patients for poten-
tial side-effects which may never occur.
We have developed a dual intervention, the Patient
Remote Intervention and Symptom Management System
(PRISMS) which combines a remote monitoring system
based on the ASyMS system developed by the authors
[36, 43] with an evidence-based nurse-led intervention
to improve patient outcomes during chemotherapy. On-
going monitoring and clinical response to patient alerts
will, therefore, be accompanied by scheduled nurse
follow-ups to ensure appropriate: usage of system func-
tionality by patients, uptake of self-care behaviours and
normalisation/reassurance that symptom alerts are ex-
pected and part of the nurses role. This intervention was
previously successfully trialled in a small Phase II trial
from which the methods remain largely unchanged.
This Phase III multi-site randomised controlled trial
will determine the effectiveness of the PRISMS interven-
tion to improve patient physical chemotherapy related
side-effects and psychological health, alongside a
cost-effectiveness analysis. This protocol describes
the methods proposed in the conduct of the Phase
III trial which is set within the Medical Research
Council (MRC) framework for evaluating complex
interventions [44].
Methods/Design
This study is a multi-site, parallel group, multi-site Phase
III randomised controlled trial. Eligible participants will
be randomised in a stratified 1:1 allocation ratio based
on factors such as cancer type to one of two arms: an
intervention arm in which the participants receive the
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PRISMS remote symptom monitoring nurse-led inter-
vention in addition to their Usual Care and a control
arm in which they receive only Usual Care.
Study setting and participants
Patients will be recruited from two institutions located
in two capital cities of two different states of Australia.
Patient inclusion criteria
Patients will be eligible to participate in the trial if they
have: a confirmed diagnosis of Hodgkin’s lymphoma,
non-Hodgkin’s lymphoma (NHL) or chronic lympho-
cytic leukaemia (CLL); are scheduled to receive at least
2 cycles of chemotherapy; are aged 18 years and over;
and are able to provide informed consent prior to com-
mencing chemotherapy treatment.
Exclusion criteria
Patients are ineligible to participate if they: are unable to
read/write/speak English sufficiently to complete study
measures; are unable to complete the study measures
due to a pre-existing disability; have an Eastern
Cooperative Oncology Group (ECOG) status of 3 or
greater; have severe cognitive or emotional issues (as
assessed by the treatment team) which could limit the
completion of the study measures or; are participating in
a conflicting drug trial such as a non-standard or trial
chemotherapy agent.
Intervention nurse selection
Senior cancer nurses from the Chemotherapy Units at
both sites will be selected by Nursing Unit Managers
and trained to deliver the intervention/respond to
PRISMS alerts during business hours. All senior nurses
in the role of Patient Service Manager at the Melbourne
site will be trained to respond to PRISMS alerts after
hours. At the Brisbane site no nurses will be trained to
respond to after-hours alerts but rather patient alerts
will be directed to the consulting haematologist to fit in
with Usual Care at this site.
Recruitment
The following recruitment processes will be tailored in
consultation with staff from each site, to ensure that
they comply with existing clinical procedures and sys-
tems. Data managers (DM) based at each site will iden-
tify eligible patients from the haematological outpatient
and chemotherapy treatment lists, with the assistance of
haematology clinicians, nurse coordinators and senior
ward staff. Eligibility will be confirmed with a member
of the treating team prior to approaching any patients to
clarify any details from the medical records, and to en-
sure the team is aware of the patient’s involvement with
the study. If a patient is considered too unwell by
his/her treatment team to participate in the study at
the time of initial screening, the patient will be excluded
from participation and will not be re-approached at a later
date. No further action will be required from the treat-
ment team.
Recruitment from clinical areas
The DM will approach eligible patients at a convenient
time before or after a medical appointment. The study
will be explained verbally and a copy of the Participant
Information and Consent Form will be provided.
Patients will be reminded that participation in the study
is voluntary and given the opportunity to ask questions.
They may take the information home for further consid-
eration. People who would like to participate will be
asked to sign the consent form (ie to provide written in-
formed consent for study participation). Those who de-
cline will be asked for verbal consent to collect basic
demographic and clinical information (including age,
sex, diagnosis and chemotherapy protocol) from their re-
cords to examine potential recruitment bias. Reasons for
refusal will be recorded when provided and no further
contact will be made with these patients. Patients who
consent to study participation will be given the Baseline
Questionnaire to complete prior to randomisation.
Recruitment via telephone
In the case where patients do not have any clinic visits
scheduled immediately prior to commencement of
chemotherapy, a DM will contact the patient by phone
following consent to approach being given by a member
of the treatment team. The DM will explain the study
verbally and ask for patient consent to post more infor-
mation about the study to the patient (i.e. the study con-
sent form and a postage paid return envelope) and
organise a time to call the patient back to address any
questions they may have. People who would like to par-
ticipate will be asked to sign the consent form. Following
receipt of a signed consent form, the DM will mail a
copy of the Baseline Questionnaire with a postage paid
return envelope. Patients will be asked to complete the
questionnaire and mail it back to the study.
Registration and randomisation
Following consent and completion of the Baseline
Questionnaire, the DM at the coordinating site will
register the participant, confirming all eligibility/registra-
tion details and will allocate a participant identification
number. The participant will be randomised by the DM
using a centralised randomisation database 1:1 to either
the control or intervention groups. Participants will be
stratified according to treating hospital, cancer type,
treatment toxicity (high versus low as predetermined by
clinical investigators based on the likelihood of patients
Breen et al. Trials  (2015) 16:472 Page 4 of 17
developing febrile neutropenia during treatment) and re-
ceipt of previous chemotherapy treatment (received no
previous chemotherapy versus received some form of
previous chemotherapy either orally or intravenously).
Minimisation will be used to balance randomisation across
strata (also known as baseline adaptive allocation) – this is
a dynamic allocation process where the probability of
a patient being allocated to a particular arm varies for
each patient being randomised, depending on the pa-
tients who have previously been randomised in the
study and their status at the stratification factors
[45, 46]. No sequence is generated in advance, instead
the randomisation database generates a set of prob-
abilities the particular patient will be allocated to an
arm, based on the above set of pre-specified rules.
The minimisation process aims to allocate equal numbers
of patients to each arm simultaneously over many strata.
The multiple strata are combined into a score for the de-
gree of imbalance between arms, and then the allocation
is made based on a coin algorithm.
Participants randomised to the intervention arm will
be scheduled for their first session with an intervention
nurse for education and training in the use of the An-
droid tablet.
Data collection
Patients
Baseline data will be collected prior to the first chemo-
therapy treatment cycle. Follow-up data will be collected
at 7 time points:
 At completion of chemotherapy treatment cycle 1
(Follow-up 1)
 Mid-cycle following of second, third and fourth
chemotherapy cycles (Follow-ups 2a, 3a and 4a)
 At completion of chemotherapy treatment cycles 2,
3 and 4 (Follow-ups 2b, 3b and 4b)
The questionnaires completed at each study time point
are summarised in Fig. 1. Data collection has been split
across 2 time periods in each treatment cycle so as to
allow the capture of side-effect and related outcomes at
a point in the cycle where they are likely to be problem-
atic (i.e. Follow-ups 2a, 3a and 4a) as the timeframe for
each of the validated outcome measures is within the
past week (i.e. Follow-ups 2a, 3a and 4a). Other mea-
sures, such as health service usage rely on data from an
entire cycle and are, therefore, measured at the conclusion
of chemotherapy treatment (CTx) cycles (i.e. Follow-ups
2b, 3b and 4b).
Follow-ups 2a, 3a and 4a will be self-completed by the
patient at home. Patients will be mailed copies of the
questionnaires (just prior to the questionnaire comple-
tion due date) along with a postage paid envelope. The
date to complete the questionnaires will be written on
the cover page and a reminder phone call on the due
date completed by the DM. Patients will be asked to
complete the questionnaires and return them in the en-
velope provided. Follow-ups 1, 2b, 3b and 4b part 1 and
2 data will be completed by patients and DM together
immediately prior to their scheduled appointments for
chemotherapy cycles 2–5.
Measures
Pen-and-paper measures
1. Demographic Questionnaire (baseline only) will be
used to assess basic patient demographic information
including: current employment status, occupation,
level of education, living arrangements and number/
age of children, country of birth, languages spoken)
and previous use of technology (including smart
phones, computers and the Internet).
2. Rotterdam Symptom Checklist (RSCL) will be used
to assess patient symptom burden. The 30-item
checklist is appropriate for use in mixed cancer
populations including those undergoing
chemotherapy, radiotherapy and/or surgery [47].
Participants use a four-point Likert-type scale to
rate the extent to which they have been bothered
by each symptom during the past week. Item
scores can be used to compute three scales including
a physical symptom distress level, psychological
distress level and activity level impairment. All
scales demonstrate acceptable internal consistency
(alpha = 0.71–0.90) and good convergent (r > 0.58)
and discriminative validity [47] and sensitivity to
change in a longitudinal setting [48].
3. Functional Assessment of Cancer Treatment –
General scale (FACT-G) questionnaire will be used
to assess patient health-related quality of life (QOL).
The 27-item FACT-G assesses four specific domains
including physical, social, emotional and functional
well-being [49]. The scaling and unidimensionality of
its subscales have been broadly confirmed by both
factor and Rasch analysis respectively [50]. FACT-G
subscales demonstrate acceptable internal
consistency (alpha = 0.72–0.90), good convergent
(r > 0.51), divergent (r < 0.22) and discriminative
validity [49] and responsiveness to psychosocial
interventions [51].
4. Hospital Anxiety and Depression Scale (HADS) will
be used to measure psychological distress [52]. The
14 items of the HADS form a uni-dimensional
construct of psychological distress [53]. HADS has
demonstrated high internal consistency (alpha = 0.85)
in cancer patients [53, 54] and responsiveness to
psychosocial interventions [55].
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Fig. 1 Flow diagram of study design
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5. EuroQol-5D (EQ-5D) descriptive system and visual
analogue scale will be used to assess health utility/
QOL. The EQ-5D is a standardised measure [56] of
health status developed specifically for economic
evaluation. In cancer patients it has acceptable
convergent validity (r > 0.49), internal consistency
(alpha = 0.71), test-retest reliability (kappa = 0.7),
discriminative validity and sensitivity to change in a
longitudinal setting [57, 58].
6. Patient Activation Measure (PAM; baseline and end
of cycle 4 only) will be used to assess patient
activation (i.e. ability to self-manage health). The
13 items of the PAM form a unidimensional
construct of knowledge, skills and confidence for
self-management. It has demonstrated high
internal consistency (alpha = 0.90) and excellent
discriminative validity based on known group
comparisons [59].
7. Cancer Treatment Scale (CaTS; baseline and end
of cycle 4 only) will be used to assess cancer
treatment-related information and support needs.
This 25 item measure forms two subscales:
sensory-psychological concerns and procedural
concerns. Both subscales demonstrated high
internal consistency (alpha > 0.90) and good
divergent validity (with the HADS: r < 0.26) [60].
Both subscales were sensitive to change in a
recent intervention study [13].
Medical record audit
Demographic and clinical data collected from the pa-
tient medical record will include: age, gender, stage of
disease; length of time since diagnosis; treatment re-
ceived in past; ECOG performance status, medications
and chemotherapy treatment regimen. Usage of hos-
pital resources will be undertaken via medical record
audit to assess emergency room presentations, un-
planned hospital admissions, total bed days of care.
Use of nursing time, allied health services, clinical in-
vestigations/procedures and other related staff time
and resource use by patients in both conditions will
be recorded. Changes in chemotherapy treatment
dose including dose reductions, and treatment delays
will also be recorded.
Structured costs interview
Use of other health services (and patient-related costs)
not recorded in the primary patient medical record,
will be assessed through the use of the Patient Health
Services and Costs Interview. This interview is con-
ducted with the patient by the DM to identify which
health- related services were utilised and any medica-
tions prescribed/used in the previous cycle in order to
assign costs.
External hospital data
In the case where DMs identify that a patient has been
treated and/or admitted to a hospital which is not the
primary treating hospital from the medical record audit
or costs interview then a letter to this external treating
hospital will be sent requesting basic details.
PRISMS electronic log data
Data from the PRISMS log files will be utilised to assess
patient compliance with daily symptom reporting and
reported use of self care activities. Log data will also be
used to assess nursing compliance with the system
including: timely response to alerts; documentation of
actions taken in response to alerts and completion of
checklists documenting scheduled interventions.
The PRISMS intervention
The PRISMS intervention is guided by 5 principles
which are linked to improved patient outcomes includ-
ing: 1) promotion of patient involvement and engagement
[13, 61]; 2) tailoring to specific need [62]; 3) emphasising
evidence based self-management [13, 63–67]; 4) involve-
ment of significant others [68] and; 5) preparing patients
for treatment and potentially threatening medical proce-
dures [13, 69–71].
The PRISMS intervention will include two synergistic-
ally operating parts: 1) a mobile phone-based remote
monitoring system with built in patient self-care advice
and clinician alerting algorithms [43]; and 2) a struc-
tured nursing support intervention relating to: patient
use of the remote monitoring system; patient coaching
in self-care strategies and ongoing access to 24-hour
nursing support/clinical interventions, triggered by real-
time system alerts.
The mobile phone enabled remote monitoring system
This system is based on the prototype previously devel-
oped and piloted [43] and based on the ASyMS system
developed by Kearney et al. [36]. Patients are provided
with a 7″ Android tablet which has the remote monitor-
ing software application installed. Patients are trained in
the use of the remote monitoring system by nurses. The
Android application prompts patients twice daily to
complete a side-effect assessment questionnaire by fol-
lowing instructions on the touch screen (Fig. 2). Patients
can also complete questionnaires at anytime they feel
unwell. The questions about common chemotherapy
related side-effects are based on the Chemotherapy
Symptom Assessment Scale [72] which measures both
severity (mild, moderate, severe) and distress (not at all,
a little, quite a bit, very much) caused by symptoms.
Symptom severity descriptors were adapted from the
Common Toxicity criteria for Adverse Events (CTCAE
V4.0) [73] for consistency in interpretation between
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patients and clinical grading of symptoms by clini-
cians. Side-effects monitored include: rigors, bleeding,
nausea, vomiting, diarrhoea, mucositis, fatigue, consti-
pation and peripheral neuropathy. Patients are also
prompted to rate their ability to complete daily living
activities [73] and to input additional parameters such
as body temperature, food intake and fluid intake into
the system. Once weekly, patients also answer ques-
tions about levels of anxiety, depression and psycho-
logical distress as well as their use of self-care
behaviours to alleviate side-effects. At the completion
of each patient questionnaire the Android application
automatically uploads and encrypts all patient ques-
tionnaire data via General Packet Radio Services to a
secure study server.
The report of any side-effects by patients completing
the questionnaire triggers the provision of tailored
evidence-based self-care advice to the patient (Fig. 3).
The self-care advice was developed from a systematic re-
view of the literature [74] and in consultation with
haematology clinicians and patient advisors, and tested
in our previous pilot study [43]. The self-care advice
consists of simple instructions to self-manage side-
effects. The patient tablet application also contains a
graphing function for patients to view their side-effects
profiles over time and an extensive library of written,
audio and video information resources (Fig. 3).
Clinician alerts The server software which receives pa-
tient data contains in-built decision support algorithms
which act to trigger Email alerts to a dedicated mobile
phone held by nurses. Alerts are divided into two
categories: red – for life-threatening or urgent issues
(eg fever) which must be addressed within 15 minutes
and; amber – for moderate/non-life-threatening issues
which should be addressed within 8 hours. Alerts are
based on those developed from a review of the litera-
ture, extensive clinician consultation and then subse-
quently piloted and refined in a previous pilot study
[42]. Alerts are based on either the severity and/or
distress relating to reported side-effects. In addition,
patients who have not completed side-effect question-
naires for > 24 hours will also generate an alert to
nurses known as a ‘missing alert’ which also requires
follow-up within 8 hours.
Upon receipt of alerts, intervention nurses will ac-
cess a secure website to view the latest patient ques-
tionnaire data. A history of patient symptoms across
cycles is provided in both tabular and graphical for-
mats to quickly orient the nurses to the patient’s situ-
ation (Figs. 4 and 5). Trained nurses contact the
patient by phone to undertake further assessment and
management. Evidence-based triage and assessment
algorithms are also provided on the secure website
alongside evidence-based self-care information to dir-
ect nursing care. Intervention nurses record all ac-
tions in a series of open fields and drop down boxes
on the secure website. Monitoring of patients (via the
SMS alerting system) occurs 24 hours/day.
Structured nursing support enabling self-management
The structured nursing support component of this inter-
vention will include 6 scheduled face-to-face or phone
intervention sessions (Fig. 6).
Fig. 2 Screenshots from the Patient Remote Intervention and Symptom Management System (PRISMS) patient remote monitoring application
illustrating: a Temperature input. b Assessment of vomiting
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 Intervention Session 1: this 50-minute face-to-face
session occurs directly following pre-chemotherapy
education and incorporates 4 components: i) training
in the use of the mobile phone remote monitoring
system; ii) eliciting and responding to patient’s key
concerns; iii) provision of evidence-based side-effect
management strategies and; iv) coaching in self-care
advice for most frequent side-effects. Coaching
involves reinforcing the importance of patients
communicating about their side-effects with the
treatment team; identifying potential barriers to
self-care, reinforcing the benefits of self-care
interventions, assisting the patient to develop
plans to overcome barriers to self-care action and
where appropriate encouraging the involvement of
the patient’s family in self-management [60–62].
Fig. 3 Screenshots from the Patient Remote Intervention and Symptom Management System (PRISMS) patient remote monitoring device
showing: a The main menu. b A graph illustrating the severity and bother due to nausea. c An excerpt of self-care information
about constipation
Fig. 4 Screenshot from the Patient Remote Intervention and Symptom Management System (PRISMS) clinician website illustrating a graphical
summary of a patient temperature profile with graph selector menu
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 Intervention Sessions 2–6 : Intervention Sessions 2
(15-minute face-to-face) and 3–6 (15-minute via
telephone) focus on answering additional patient
questions about treatment or use of the system,
coaching in use of self-care and utilisation of the
full functionality of the PRISMS tablet computer
application (Fig. 6).
Quality control
Training intervention nurses
At each site specialist cancer nurses will be trained to
provide scheduled patient interventions during business
hours and to respond to real-time patient generated sys-
tem alerts. Training will take place in 2 sessions of
4 hours and consists of: a project overview; developing
familiarity and skills in the use of the remote monitor-
ing/management system and responding to system alerts;
communication skills training for in eliciting and respond-
ing to emotional cues; coaching in self-care strategies and;
role-play scenarios with simulated patients. A detailed
intervention manual containing all aspects of the training
as well as evidence-based self-care algorithms will also be
provided to all intervention nurses.
After hours nurses
After hours nurses will be trained in how to respond
to real-time patient generated system alerts using the
website. A short manual containing instructions on
how to respond to alerts and use the website will be
provided.
Data manager training
DMs with experience in participant recruitment and co-
ordinating research projects will be trained to identify
eligible patients, liaise with hospital staff and interven-
tion nurses, approach patients, randomise consenting
patients, administer pen-and-paper outcome measures
and interviews at all data collection time points, manage
participant databases, and report data back to the pro-
ject team.
Quality assurance of the intervention
All scheduled face-to-face and phone interventions will be
digitally recorded for assessment of content and adher-
ence to the intervention manual. Intervention nurses will
also be required to record all interactions and interven-
tions within the PRISMS website from drop down menus/
open text boxes. Completeness of intervention delivery
can then be assessed for adherence to the intervention
manual with data from both the recorded conversations
and data entered into the website. The time taken for
intervention nurses to respond to red/amber alerts will be
recorded automatically by the website to ensure that alerts
are responded to within designated time frames. All
nurses involved in the study, will have access to evidence-
based algorithms/self-care strategies for managing patient
side-effects on the system. Nursing responses to real-time
patient alerts documented on the system will be assessed
for compliance with triage algorithms provided.
Patient adherence to daily completion of side-effect
questionnaires with the Android application will be
Fig. 5 Screenshot from the Patient Remote Intervention and Symptom Management System (PRISMS) clinician website illustrating history of
individual patient alerts and side-effects reported
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assessed for timeliness and patient use of the prescribed
self-care information provided by the Android applica-
tion will also be monitored with a weekly self-report
questionnaire.
Diffusion of the intervention
Diffusion of an intervention relates to how a novel
idea or practice spreads through a population – for
example the adoption of a new behaviour. In the case
of an intervention study such as PRISMS, it is pos-
sible that nurses trained to deliver the PRISMS inter-
vention may discuss novel practices with nurses
delivering Usual Care; thus changing Usual Care and
diluting the potential overall intervention effect. In a
previous study of a pre-CTx education intervention
[13] we successfully trained a subgroup of Day
Chemotherapy Unit nurses for intervention delivery.
A random analysis of recordings from both control
and intervention group education sessions subse-
quently showed no evidence of diffusion over time. In
this study diffusion will be minimised by: 1) instruct-
ing intervention nurses about the effects of diffusion/
impact on study outcomes; 2) intervention nurses not
treating control group patients and; 3) control group
patients not using the remote monitoring system
thereby removing the alerts which structure a large
component of the intervention.
Nurses who monitor real-time alerts after hours will
not be able to avoid potentially providing care to control
group patients who may ring the switchboard for infor-
mation/clinical advice. However, when these nurses
manage control group patients they will not have ready
access to the evidence-based triage algorithms/self-care
information located on the system website or data from
side-effect history profiles available to intervention
patients.
Fig. 6 Summary flow diagram of the Patient Remote Intervention and Symptom Management System (PRISM) intervention (Abbreviations: C1D1,
Day 1 of chemotherapy treatment cycle 1; C2D1, Day 1 of chemotherapy treatment cycle 2; C3D1, Day 1 of chemotherapy treatment cycle 3;
C4D1, Day 1 of chemotherapy treatment cycle 4)
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Standard of care
Control group
Patients allocated to the control group will receive the fol-
lowing resources from the DM following randomisation:
an evidence-based patient preparation for chemotherapy
DVD [13]; a standard booklet ‘Introduction to Chemother-
apy’; and standard drug information sheets. Control group
patients will receive pre-chemotherapy education as per
Usual Care at each site. They will also have routine access
to the haematology treatment team at each site via: i)
scheduled clinic visits, and ii) via hospital switchboards at
other times.
Intervention group
Patients allocated to the intervention condition will receive
standard care as described above in the control group. In
addition they will also receive the PRISMS intervention.
Safety of the intervention
The intervention is not designed to replace normal pa-
tient contact with the hospital (i.e. Usual Care) but to
enhance the current Usual Care. The patient Android
application comes equipped with emergency and hos-
pital phone numbers for patient reference and the tablet
computer provided can also be used as a phone to con-
tact the hospital when required. Should an error occur
in the transmission of patient side-effect data from the
patient tablet to the system server/website the software
application will advise the patient of the failure of data
transmission and, based on alerting algorithms, provide
detailed instructions on who and when to call. The ser-
ver containing the system is monitored daily for per-
formance and any faults addressed by technicians.
Outcomes
Primary hypothesis
Compared to the Usual Care control group, participants
receiving the PRISMS intervention will report lower
scores item scores for nausea, mucositis, constipation
and fatigue of at least 0.4 standard deviations at follow-
up (mid-cycle 2 of chemotherapy treatment).
Secondary hypotheses
Specific secondary hypotheses are that:
1. Participants receiving the PRISMS intervention will
report lower scores on item scores for nausea,
mucositis, constipation and fatigue compared to the
Usual Care control group at follow-up (mid-cycles 3
and 4);
2. Participants receiving the PRISMS intervention will
report lower item scores for vomiting and diarrhoea
compared to the Usual Care control group at
follow-up (mid-cycles 2, 3 and 4);
3. Participants receiving the PRISMS intervention will
report lower levels of psychological distress, better
quality of life, higher levels of patient activation
(ability to self-manage health) and lower levels of
cancer information and support needs compared to
the Usual Care control group at follow-up
(mid-cycles 2, 3 and 4); and
4. The PRISMS intervention will be cost-effective com-
pared to the Usual Care comparator at follow-up
(end of chemotherapy cycles 2, 3, and 4).
Primary and secondary hypotheses for nausea, mu-
cositis, constipation and fatigue differ only in the pre-
dicted chemotherapy cycle. This is based on previous
qualitative data relating to the PRISMS intervention
which suggested that patients find the system to have
greatest value in cycles 1 and 2 as well as the issue
that not all patients who are originally scheduled to
receive 4 cycles of treatment go on to complete all
cycles.
Sample size
Primary outcomes are nausea, mucositis, constipa-
tion and fatigue as assessed by the RSCL items la-
belled ‘nausea’, ‘sore mouth/difficulty swallowing’,
‘constipation’ and ‘tiredness’ respectively. All items
have a possible scale range of 1 to 4 (corresponding
to a rating of ‘not at all’, ‘a little’, ‘quite a bit’ and
‘very much’ respectively) with higher scores indicat-
ing a higher levels of burden or impairment. These
outcomes were chosen because they are common in
patients receiving chemotherapy, are targeted by the
PRISMS intervention and have demonstrated im-
provement following Telehealth interventions [33].
Sample size calculations were based on 80 % power, a
2-sided independent-samples t test with an alpha level of
0.05 and a standardised effect size of 0.4. In the absence
of minimal important difference estimates for the RSCL,
or any other symptom assessment tool validated for use
in cancer patients, evidence-based effect sizes for the
EORTC QLQ-C30 symptom scales and individual items
were used as a guide [75, 76]. In this case, for all QLQ-
C30 scales/items excepting the dyspnoea item, a standar-
dised effect of 0.4 represents the lower threshold of a
medium-sized clinically relevant difference between
groups of cancer patients. Given these specifications, a
total of 200 patients (100 per arm) is required. Assuming
attrition of up to 10 %, a total of 222 patients (111 per
arm) are needed at baseline.
Recruitment
Based upon recruitment/retention statistics collected in
the Phase II trial at the Melbourne site in 2012–13, and
upon the predicted eligible patient population presenting
Breen et al. Trials  (2015) 16:472 Page 12 of 17
at the Brisbane site, we estimate that around 108 pa-
tients will be recruited in 12 months across the 2 sites
with total recruitment time of approximately 25 months.
Analyses
Quantitative
All data will be entered into Microsoft Excel 2003 (or
higher) (Microsoft Inc., Redmond, WA, USA) then
imported into SPSS Windows Version 21 (or higher)
(SPSS, Chicago, IL, USA) for scoring and analysis. R ver-
sion 3.0.1 (or higher) and the R package ‘ggplot2’ will be
used to prepare all graphs and plots [77].
Prior to formal analysis, descriptive statistics and
graphical displays will be used to identify missing and
out-of-range values, assess the plausibility of means and
standard deviations (SDs) for all variables and identify
outliers and screen continuous variables for normality.
Recruitment bias
Recruitment bias will be assessed by comparing demo-
graphic and clinical variables of patients who consent to
participate and those who decline participation using t
tests (or Mann-Whitney U) and chi-squared (or Fisher’s
exact) tests as appropriate.
Differential attrition
Possible differential attrition will be assessed by com-
paring baseline characteristics of drop-outs and con-
tinuing participants using t tests (or Mann-Whitney
U tests) and chi-squared (or Fisher’s exact) tests as
appropriate.
Outcome analyses
Analyses will be by intention-to-treat. Primary and sec-
ondary outcome analyses will be carried out by fitting a
linear mixed model to each outcome separately using all
available data. A cell mean model (suppressing the de-
fault intercept) will be used to estimate mean scores for
each group (study arm) by time combination; all models
will include a fixed group by time effect and no random
effects [78]. An unstructured covariance type will be
used to model the covariance structure among repeated
measures and all models will be estimated by maximum
likelihood. The primary analysis will be group compari-
sons at post-baseline time points; these will be per-
formed using contrasts within the proposed models. The
group by time interaction will be used to assess the over-
all pattern of change [79]. A ‘toxicity’ by group by time
interaction will be added to each model to assess
whether participants receiving chemotherapy protocols
classified as either ‘low-toxicity’ or ‘high toxicity’ re-
spond differently to the PRISMS intervention. Adjusted
analysis including using baseline responses to study
measures and the remaining stratification factors will
also be investigated.
After inspection of the data, the appropriateness of
suggested methods will be assessed and revised as neces-
sary. Specific emphasis will be placed on assessing
models proposed for the analysis of primary and second-
ary outcomes that are measured on an ordinal scale; that
is, nausea, mucositis, constipation and fatigue as
assessed by the RSCL. When applied to ordinal out-
comes, models for continuous outcomes can yield biased
estimates of regression coefficients. When the distri-
bution of scores on ordinal variables is highly skewed,
this bias may be large and the use of methods specif-
ically designed for ordered data is recommended [80].
In this case, if graphical exploration of the data and/
or regression diagnostics indicates violation of model
assumptions, relevant analyses will be carried out by
fitting an ordinal logistic generalised linear mixed
model to each outcome separately using methods de-
scribed by Hedeker [81]. In brief, fully parameterised
models will include fixed effects for group, time plus
a group by time interaction, as well as random sub-
ject and time effects.
Exploratory analyses
Linear regression models will be used to explore predic-
tors of health-related quality of life and psychological
distress at baseline. Growth curve models will be used to
explore associations between baseline characteristics and
longitudinal outcome data in the control group. Linear
regression models will also be used to explore predictors
of health services utilisation.
Intervention compliance
Frequency statistics (i.e. raw counts and averages) will be
used to summarise data relevant to patient/nurse inter-
vention compliance. This data will come from two
sources: the electronic log of the PRISMS system and
digital recordings of face-to-face and phone intervention
sessions.
PRISMS electronic log files
With respect to patient data this will include: frequency
of < 2 symptom questionnaires being completed within a
24-hour period; Frequency of ‘missing alerts’ generated
(i.e. no symptom questionnaires submitted within a
24-hour period); Frequency of missing weekly self-
care use questionnaires.
With respect to nursing data this will include: fre-
quency of red alerts responded to within designated
timeframe (i.e. 15 minutes) as measured by login to
secure server; frequency of amber alerts responded to
within designated timeframe (i.e. 8 hours) as mea-
sured by login to secure server; frequency of missing
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alerts responded to within designated timeframe (i.e.
8 hours) as measured by login to secure server; fre-
quency of documentation of actions taken in response
to alerts and completion of checklists for scheduled
interventions.
Digital recordings
A content checklist has been developed to assess ‘inter-
vention completeness’ for each intervention time point.
Checklists will be based on the nursing intervention
manual as previously developed by the research team. A
sub-set of recordings (20 %) will be listened to by 2
members of the research team and a percentage com-
pleteness figure calculated.
Economic evaluation
Cost utility analysis (a form of cost-effectiveness ana-
lysis), measures benefits in quality- adjusted life years
(QALYS). This will allow for the comparison of effi-
ciency of patients receiving the PRISMS intervention
and those receiving Usual Care in terms of cost-per-
QALY gained. Analyses will be undertaken both from a
broad societal perspective in addition to a health care
perspective.
The incremental cost of the intervention will be com-
pared to the incremental health outcome improvement
attributed to the intervention. Results will be expressed
as cost per QALY gained (i.e. the incremental cost-
effectiveness ratio (ICER) will be determined for patients
receiving either the PRISMS intervention or Usual Care)
within the trial period and projected beyond the trial
period using appropriate economic modelling. Uncer-
tainty in the cost and outcome data will be further eval-
uated via sensitivity analyses whereby key evaluation
parameters (such as unit costs) are varied to assess the
impact on study conclusions.
Economic measures for both benefits and costs utilised
in these analyses include the EQ-5D as a utility measure
of patient quality of life; the Health Services and Costs
Questionnaire to determine use of health care services
and medicines and; a medical record (MR) audit of both
treating hospital records and any external hospital re-
cords (eg emergency admissions). More specifically, MR
audits and the Health Services Usage and Costs
Questionnaire will document: emergency room presen-
tations, planned/unplanned hospital admissions, total
bed days of care and reasons of hospitalisation, use of
nursing/allied health resources, clinical investigations,
medications prescribed (including chemotherapy and
dose reductions and treatment delays), use of commu-
nity health resources (eg general practitioners (GPs),
allied health), use of alternative therapies, community
services (eg meals on wheels); use of transport; days out
of role (paid/unpaid) for both patients and carers,
alongside any other costs incurred to patients/carers as a
result of their cancer treatment. Data collection will
cover both that paid for by the individual (before/with-
out rebate) and also that paid for by third parties (eg re-
bated dollar amount by Medicare or private health
insurance companies). Calculation of the cost of the
PRISMS intervention itself will include only the costs of
the intervention delivery (i.e. excluding development or
research costs). Research team records (eg PRISMS web-
site; data transmission costs, training time/materials) will
be used to determine the cost of the intervention. Mea-
sured resource use will be valued using existing unit
costs such as the National Hospital Cost Data
Collection-Cost Report; Australian Refined Diagnosis
Related Groups for inpatient health costs, Medicare
Benefits Schedule for outpatient costs, Pharmaceutical
Benefit Scheme for pharmaceutical costs and Australian
Bureau of Statistics for estimates of Australian earnings
for productivity effects.
Ethical issues
The study protocol has been ethically approved by insti-
tutional ethical review committees at both participating
sites (Peter MacCallum Cancer Centre Human Research
Ethics Committee and Bellberry Human Research Ethics
Committee for ICON Cancer Care). The rights and wel-
fare of the participants will be protected according to
the National Health and Medical Research Council of
Australia’s National Statement on Ethical Conduct in
Human Research. Clinical care and emergency medical
services are provided by participating institutions. Data
that is collected as part of the study will not be linked to
any individual.
Discussion
The proposed system combines cutting edge technology
with systematic evidence-based, nursing consultation. It
is internationally innovative and tailored to the real-time
monitoring of CTx toxicities and the provision of tai-
lored self-care to address individual needs. Given the
aging of the Australian population and the consequent
expected increase in people diagnosed with cancer, it is
imperative to find cost-effective strategies to improve
the quality and safety of cancer care in the community
whilst improving patient outcomes. These systems are
most critical where CTx treatment has a high-risk of
toxicity and potentially life-threatening consequences
leading to unplanned hospitalisations, such as with
haematological malignancies, including leukaemia and
lymphoma. The development of Telehealth systems and
interventions which allow for the real-time remote mon-
itoring and management of high risk patients during
treatment are, therefore, a priority.
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Methodological rigour
This study will be the first technology-mediated
nurse-led intervention study for cancer patients that
meets the Consolidated Standards of Reporting Trials
(CONSORT) criteria for randomised controlled trials
[82] and fits within the MRC framework for the ana-
lysis of complex interventions [44]. Participants will
be randomly allocated by a computer after eligibility
assessment and the collection of baseline data. Inter-
vention procedures will be strictly monitored for
protocol adherence. The relatively short follow-up
period will minimise dropout. Reasons for attrition
will be recorded, and recruitment and dropout bias
assessed. Blinding of patients and providers cannot be
achieved with this study design. However, outcome
assessment will be by patient self-report question-
naire, obviating the need for researcher blinding. A
previous shortcoming of similar research [33] is the
lack of knowledge of patient adherence to completing
self-care behaviours when interpreting study out-
comes. This system is, therefore, also unique in its
ability to regularly measure patient adherence to self-
care behaviours for key side-effects. Quantitative
assessment of both nursing and patient intervention
compliance will also be invaluable in guiding system
or intervention changes needed to maximise system
useability and intervention compliance for future
studies.
As the intervention has been grounded in the current
nursing models of patient care, alongside the develop-
ment of detailed study training materials, the roll-out of
the intervention to routine clinical practice following a
successful Phase III trial could also be completed rela-
tively efficaciously. The suitability of the system for both
in-patient and out-patient treatment populations also
makes it widely applicable to a range of chemotherapy
treatment protocols.
The PRISMS intervention is innovative and tailored
to the real-time monitoring of chemotherapy toxicities
and the provision of tailored self-care to address indi-
vidual needs. It is the first system designed to specif-
ically monitor adult patients with haematological
cancers undergoing chemotherapy. It is also the first
randomised controlled trial of any Telehealth- medi-
ated nurse-led intervention for cancer patients and
builds from earlier ASyMS work and will, in tandem
with the current large European (>1000 patients)
ASyMS randomised controlled trial, add to our grow-
ing knowledge of the impact of these interventions on
patient health outcomes and health system costs.
Nursing interventions, combined with remote moni-
toring systems, such as those described in this proto-
col, are, therefore, likely to enable both more accurate
symptom monitoring and management, combined
with greater efficiency and effectiveness of nursing
roles in haematology.
Trial status
This trial is currently in the process of recruiting
patients.
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